Roivant Sciences (ROIV) Financial Analysis & Valuation | Quarter Chart
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, a... more
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and dev... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $26.36B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Matthew Gline |
| IPO Date | 2020-12-08 | CAGR | -29.57% |
| Employees | 721 | Website | roivant.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.7% | Total Yield | 0.7% |
ROIV chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $24.67B | P/E | -34.72 | Forward P/E | -21.8 | PEG | — |
| P/S | 5861.94 | P/B | 10.39 | P/CF | -54 | P/FCF | -53.83 |
| Sales | $7.53M | Sales 1Y | -67.58% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-1.05 | EPS 1Y | -37.14% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -42.78% | EPS QoQ | -170.27% | Sales QoQ Avg | -4.27% | EPS QoQ Avg | -73.15% |
| Gross Margin | 81.21% | Operating Margin | -18140.92% | Profit Margin | -3534.96% | ROCE | -27.2% |
| ROA | -5% | ROE | -6% | Altman Z Score | 40.21 | Piotroski Score | — |
| Current Ratio | 16.72 | Quick Ratio | 16.72 | Cash Ratio | 4.4 | Op. CF Ratio | -0.93 |
| Debt/Equity | 0.03 | Debt/Assets | 0.02 | Lt Debt/Equity | 0.02 | Lt Debt/Cap. | 0.02 |
| Intrst Cov. | -37.01 | Inventory Turnover | — | Asset Turnover | 0 | Receivables Turnover | — |
| Enterprise Value | $24.67B | P/E Ratio | -34.72 |
| Forward P/E | -21.8 | PEG Ratio | — |
| P/S Ratio | 5861.94 | P/B Ratio | 10.39 |
| P/CF Ratio | -54 | P/FCF Ratio | -53.83 |
| EPS | $-1.05 | EPS Growth 1Y | -37.14% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -67.58% | Gross Margin | 81.21% |
| Operating Margin | -18140.92% | Profit Margin | -3534.96% |
| ROE | -6% | ROA | -5% |
| ROCE | -27.2% | Current Ratio | 16.72 |
| Quick Ratio | 16.72 | Cash Ratio | 4.4 |
| Debt/Equity | 0.03 | Interest Coverage | -37.01 |
| Altman Z Score | 40.21 | Piotroski Score | — |
Roivant Sciences (ROIV) valuation & financials
Roivant Sciences (ROIV) has a market capitalization of $26.36B and trades at a price-to-earnings ratio of -34.7. It operates in the Healthcare sector (Biotechnology).
Roivant Sciences's revenue grew -67.6% over the last year.
Roivant Sciences's next earnings report is scheduled for November 9, 2026 (provider scheduled date); analysts estimate EPS of $-0.37. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)